MDACC Study No:2008-0062 ( NCT No: NCT00670592)
Title:A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapies
Principal Investigator:Michelle A. Fanale
Treatment Agent:HCD122
Study Status:Terminated
Study Description:This study is being done in 2 parts. The goal of Part 1 of the study is to
find the highest tolerable dose of HCD122 that can be given to patients with
advanced non-Hodgkin's lymphoma or Hodgkin's lymphoma. The goal of Part 2 of
the study is to learn if HCD122 can affect the disease. The safety of HCD122
will also be studied.

This consent form is for both Part 1 and Part 2 of the treatment portion of
this study.
Currently, this study is enrolling patients for Part 2 because Part 1 has been
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:HCD122
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Novartis
Return Visit:Screening Day (within 28 days of infusion). Days 1, 2, 3, 5, 8, 15, 22, 23, 24,
26, 29, 36, 43, 50, 106. Follow-up visit on Day 162 and End of Study visit.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults